Effect of baseline characteristics on prostate cancer rates and risk reduction in the Reduction by Dutasteride of prostate Cancer Events REDUCE) trial

被引：0
|
作者：
Andriole, G. [1 ]
Brawley, O. [2 ]
Gomella, L. [3 ]
Marberger, M. [4 ]
Montorsi, F. [5 ]
Pettaway, C. [6 ]
Teloken, C. [7 ]
Tammela, T. [8 ]
Tindall, D. [9 ]
Rittmaster, R. [10 ]
机构：
[1] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[4] Univ Vienna, Dept Urol, Vienna, Austria
[5] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Fed Med Sch FFCMPA, Dept Urol, Alegre, Brazil
[8] Tampere Univ Hosp, Div Urol, Tampere, Finland
[9] Mayo Clin & Mayo Grad Sch Med, Dept Urol, Rochester, MN USA
[10] GlaxoSmithKline Inc, Urol Med Dev, Res Triangle Pk, NC USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71384-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：407 / 408
页数：2
相关论文
共 50 条
  • [31] The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.
    Bostwick, D. G.
    Tindall, D. J.
    Pettaway, C. A.
    Tammela, T. L.
    Teloken, C.
    Wilson, T. H.
    Castro, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Worldwide comparison of prostate needle biopsy quality in the reduction by dutasteride of prostate cancer events (REDUCE) study: Improvement with investigator training
    Bostwick, D. G.
    Teloken, C.
    Brawley, O. W.
    Marberger, M.
    Qian, J.
    Drewnowska, K.
    Niyuhire, F.
    Rittmaster, R. R.
    Fowler, I. L.
    Somerville, M. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Efficacy and Safety of Dutasteride on Prostate Cancer Risk Reduction in Asian Men: The Results from the REDUCE Study
    Akaza, Hideyuki
    Kanetake, Hiroshi
    Tsukamoto, Taiji
    Miyanaga, Naoto
    Sakai, Hideki
    Masumori, Naoya
    Nakatsu, Hiroomi
    Sagiyama, Kazuyuki
    Sakamoto, Sadaaki
    Endo, Yukihiro
    Yamanouchi, Takayoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : 417 - 423
  • [34] EVALUATION OF SAFETY AND ABILITY OF DUTASTERIDE TO IMPROVE URINARY PARAMETERS IN SUBJECTS WITH LOW TESTOSTERONE IN THE REDUCTION BY DUTASTERIDE IN PROSTATE CANCER EVENTS (REDUCE) STUDY
    Marberger, Michael
    Freedland, Stephen
    Rittmaster, Roger
    Wilson, Timothy
    Castro, Ramiro
    JOURNAL OF UROLOGY, 2013, 189 (04): : E564 - E565
  • [35] Re: Effect of Dutasteride on the Risk of Prostate Cancer
    Klotz, Laurence
    EUROPEAN UROLOGY, 2010, 58 (02) : 313 - 313
  • [36] Effect of Dutasteride on the Risk of Prostate Cancer.
    Andriole, Gerald L.
    Bostwick, David G.
    Brawley, Otis W.
    Gomella, Leonard G.
    Marberger, Michael
    Montorsi, Francesco
    Pettaway, Curtis A.
    Tammela, Teuvo L.
    Teloken, Claudio
    Tindall, Donald J.
    Somerville, Matthew C.
    Wilson, Timothy H.
    Fowler, Ivy L.
    Rittmaster, Roger S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13): : 1192 - 1202
  • [37] Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial
    Crawford, E. David
    Andriole, Gerald L.
    Marberger, Michael
    Rittmaster, Roger S.
    UROLOGY, 2010, 75 (03) : 502 - 509
  • [38] Re: Effect of Dutasteride on the Risk of Prostate Cancer
    Sooriakumaran, Prasanna
    Tewari, Ashutosh
    EUROPEAN UROLOGY, 2010, 58 (03) : 465 - 466
  • [39] Re: Effect of Dutasteride on the Risk of Prostate Cancer
    Bosland, Maarten C.
    Cremers, Ruben G. H. M.
    Kiemeney, Lambertus A.
    EUROPEAN UROLOGY, 2010, 58 (04) : 631 - 632
  • [40] GSK Statement on Avodart™ (Dutasteride) for Prostate Cancer Risk Reduction Editorial Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2011, 186 (02): : 530 - 530
12345